File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0023616670
- PMID: 2889081
- WOS: WOS:A1987K475600003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Placebo-controlled trial of recombinant α2-interferon in Chinese HBsAg-carrier children
Title | Placebo-controlled trial of recombinant α2-interferon in Chinese HBsAg-carrier children |
---|---|
Authors | |
Issue Date | 1987 |
Publisher | The Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet |
Citation | Lancet, 1987, v. 2 n. 8564, p. 877-880 How to Cite? |
Abstract | 24 Chinese children aged 1.5-5 years and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus DNA polymerase (HBV DNAp), and HBV DNA on at least three occasions in the 6 months before the trial were randomised to receive either vitamin B complex or intramuscular recombinant α2-interferon (r-IFN) ('Roferon') 10 x 106 IU/m2 thrice weekly for 12 weeks. In all 12 subjects receiving r-IFN, HBV DNAp and HBV DNA levels fell during the course of r-IFN injections. Within 4 weeks of cessation of r-IFN injection, the HBV DNAp and HBV DNA returned to pre-trial levels except in 2 subjects, in whom loss of HBV DNAp and HBV DNA was sustained for up to 18 months from onset of the trial. 1 child lost HBeAg at 18 months, 2 of the 12 children in the placebo group also had a sustained loss of HBV DNAp and HBV DNA during the 18 months, with 1 child losing HBeAg at 18 months. All 24 subjects remained positive for HBsAg. r-IFN produced very slight side-effects except for pyrexia and the 'flu' syndrome, both of which showed rapid tachyphylaxis. In the dose given r-IFN was safe but had no long-term beneficial effects on HBsAg carriage in Chinese children. |
Persistent Identifier | http://hdl.handle.net/10722/161737 |
ISSN | 2023 Impact Factor: 98.4 2023 SCImago Journal Rankings: 12.113 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Lin, HJ | en_US |
dc.contributor.author | Yeoh, EK | en_US |
dc.contributor.author | Lok, ASF | en_US |
dc.contributor.author | Wu, PC | en_US |
dc.contributor.author | Yeung, CY | en_US |
dc.date.accessioned | 2012-09-05T05:14:33Z | - |
dc.date.available | 2012-09-05T05:14:33Z | - |
dc.date.issued | 1987 | en_US |
dc.identifier.citation | Lancet, 1987, v. 2 n. 8564, p. 877-880 | en_US |
dc.identifier.issn | 0140-6736 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/161737 | - |
dc.description.abstract | 24 Chinese children aged 1.5-5 years and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus DNA polymerase (HBV DNAp), and HBV DNA on at least three occasions in the 6 months before the trial were randomised to receive either vitamin B complex or intramuscular recombinant α2-interferon (r-IFN) ('Roferon') 10 x 106 IU/m2 thrice weekly for 12 weeks. In all 12 subjects receiving r-IFN, HBV DNAp and HBV DNA levels fell during the course of r-IFN injections. Within 4 weeks of cessation of r-IFN injection, the HBV DNAp and HBV DNA returned to pre-trial levels except in 2 subjects, in whom loss of HBV DNAp and HBV DNA was sustained for up to 18 months from onset of the trial. 1 child lost HBeAg at 18 months, 2 of the 12 children in the placebo group also had a sustained loss of HBV DNAp and HBV DNA during the 18 months, with 1 child losing HBeAg at 18 months. All 24 subjects remained positive for HBsAg. r-IFN produced very slight side-effects except for pyrexia and the 'flu' syndrome, both of which showed rapid tachyphylaxis. In the dose given r-IFN was safe but had no long-term beneficial effects on HBsAg carriage in Chinese children. | en_US |
dc.language | eng | en_US |
dc.publisher | The Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet | en_US |
dc.relation.ispartof | Lancet | en_US |
dc.subject.mesh | Carrier State - Therapy | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Clinical Trials As Topic | en_US |
dc.subject.mesh | Dna, Viral - Analysis | en_US |
dc.subject.mesh | Dna-Directed Dna Polymerase - Analysis | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-Up Studies | en_US |
dc.subject.mesh | Hepatitis B - Therapy | en_US |
dc.subject.mesh | Hepatitis B Surface Antigens - Analysis | en_US |
dc.subject.mesh | Hepatitis B Virus - Enzymology | en_US |
dc.subject.mesh | Hong Kong | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Injections, Intramuscular | en_US |
dc.subject.mesh | Interferon Type I - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Random Allocation | en_US |
dc.subject.mesh | Recombinant Proteins - Administration & Dosage - Therapeutic Use | en_US |
dc.title | Placebo-controlled trial of recombinant α2-interferon in Chinese HBsAg-carrier children | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lai, CL:hrmelcl@hku.hk | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 2889081 | - |
dc.identifier.scopus | eid_2-s2.0-0023616670 | en_US |
dc.identifier.volume | 2 | en_US |
dc.identifier.issue | 8564 | en_US |
dc.identifier.spage | 877 | en_US |
dc.identifier.epage | 880 | en_US |
dc.identifier.isi | WOS:A1987K475600003 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_US |
dc.identifier.scopusauthorid | Lin, HJ=7405571292 | en_US |
dc.identifier.scopusauthorid | Yeoh, EK=35427828500 | en_US |
dc.identifier.scopusauthorid | Lok, ASF=35379868500 | en_US |
dc.identifier.scopusauthorid | Wu, PC=7403119323 | en_US |
dc.identifier.scopusauthorid | Yeung, CY=7201354144 | en_US |
dc.identifier.issnl | 0140-6736 | - |